150 related articles for article (PubMed ID: 35946590)
1. Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.
Langbaum JB; Zissimopoulos J; Au R; Bose N; Edgar CJ; Ehrenberg E; Fillit H; Hill CV; Hughes L; Irizarry M; Kremen S; Lakdawalla D; Lynn N; Malzbender K; Maruyama T; Massett HA; Patel D; Peneva D; Reiman EM; Romero K; Routledge C; Weiner MW; Weninger S; Aisen PS
Alzheimers Dement; 2023 Feb; 19(2):696-707. PubMed ID: 35946590
[TBL] [Abstract][Full Text] [Related]
2. Modifiable Barriers for Recruitment and Retention of Older Adults Participants from Underrepresented Minorities in Alzheimer's Disease Research.
Indorewalla KK; O'Connor MK; Budson AE; Guess DiTerlizzi C; Jackson J
J Alzheimers Dis; 2021; 80(3):927-940. PubMed ID: 33612540
[TBL] [Abstract][Full Text] [Related]
3. Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer's Disease.
Park L; Kouhanim C; Lee S; Mendoza Z; Patrick K; Gertsik L; Aguilar C; Gullaba D; Semenova S; Jhee S
J Prev Alzheimers Dis; 2019; 6(2):135-138. PubMed ID: 30756120
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.
Vellas B; Hampel H; Rougé-Bugat ME; Grundman M; Andrieu S; Abu-Shakra S; Bateman R; Berman R; Black R; Carrillo M; Donohue M; Mintun M; Morris J; Petersen R; Thomas RG; Suhy J; Schneider L; Seely L; Tariot P; Touchon J; Weiner M; Sampaio C; Aisen P;
J Nutr Health Aging; 2012 Apr; 16(4):339-45. PubMed ID: 22499454
[TBL] [Abstract][Full Text] [Related]
5. Challenges to and Facilitators of Recruitment to an Alzheimer's Disease Clinical Trial: A Qualitative Interview Study.
Clement C; Selman LE; Kehoe PG; Howden B; Lane JA; Horwood J
J Alzheimers Dis; 2019; 69(4):1067-1075. PubMed ID: 31156168
[TBL] [Abstract][Full Text] [Related]
6. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials.
Vellas B; Pesce A; Robert PH; Aisen PS; Ancoli-Israel S; Andrieu S; Cedarbaum J; Dubois B; Siemers E; Spire JP; Weiner MW; May TS
Alzheimers Dement; 2011 Jul; 7(4):e109-17. PubMed ID: 21784343
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
[TBL] [Abstract][Full Text] [Related]
8. Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer's Disease Research.
Boada M; Santos-Santos MA; Rodríguez-Gómez O; Alegret M; Cañabate P; Lafuente A; Abdelnour C; Buendía M; de Dios MJ; Morera A; Sanabria Á; Campo L; Ruiz A; Tárraga L
J Alzheimers Dis; 2018; 62(3):1079-1090. PubMed ID: 29562541
[TBL] [Abstract][Full Text] [Related]
9. Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report.
Raman R; Aisen PS; Carillo MC; Detke M; Grill JD; Okonkwo OC; Rivera-Mindt M; Sabbagh M; Vellas B; Weiner M; Sperling R
J Prev Alzheimers Dis; 2022; 9(3):388-392. PubMed ID: 35841239
[TBL] [Abstract][Full Text] [Related]
10. Obstacles and opportunities in Alzheimer's clinical trial recruitment.
Watson JL; Ryan L; Silverberg N; Cahan V; Bernard MA
Health Aff (Millwood); 2014 Apr; 33(4):574-9. PubMed ID: 24711317
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. Task force on Alzheimer's disease trial methodology: recruitment and retention, data management and analysis. The use of imaging in recruitment: maintenance and methodological issues in Alzheimer's trials.
Suhy J
J Nutr Health Aging; 2012 Apr; 16(4):349-51. PubMed ID: 22499456
[TBL] [Abstract][Full Text] [Related]
13. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD).
Walter S; Clanton TB; Langford OG; Rafii MS; Shaffer EJ; Grill JD; Jimenez-Maggiora GA; Sperling RA; Cummings JL; Aisen PS
J Prev Alzheimers Dis; 2020; 7(4):219-225. PubMed ID: 32920623
[TBL] [Abstract][Full Text] [Related]
14. Insights and recommendations for working collaboratively and improving care in Alzheimer's disease: Learnings from the Finding Alzheimer's Solutions Together (F.A.S.T.) Council.
Roeser J; Bayliss N; Blom M; Croney R; Lanman L; Laks J; Lyons M; Proulx L; Tsatali M; Westerlund K; Georges J
Health Expect; 2024 Apr; 27(2):e14040. PubMed ID: 38629481
[TBL] [Abstract][Full Text] [Related]
15. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
[TBL] [Abstract][Full Text] [Related]
16. "From Victimhood to Warriors": Super-researchers' Insights Into Alzheimer's Disease Clinical Trial Participation Motivations.
Bardach SH; Parsons K; Gibson A; Jicha GA
Gerontologist; 2020 May; 60(4):693-703. PubMed ID: 31322657
[TBL] [Abstract][Full Text] [Related]
17. Recruitment and Screening Methods in Alzheimer's Disease Research: The FIT-AD Trial.
Greimel S; Wyman JF; Zhang L; Yu F
J Gerontol A Biol Sci Med Sci; 2022 Mar; 77(3):547-553. PubMed ID: 33780529
[TBL] [Abstract][Full Text] [Related]
18. Building a roadmap for developing combination therapies for Alzheimer's disease.
Perry D; Sperling R; Katz R; Berry D; Dilts D; Hanna D; Salloway S; Trojanowski JQ; Bountra C; Krams M; Luthman J; Potkin S; Gribkoff V; Temple R; Wang Y; Carrillo MC; Stephenson D; Snyder H; Liu E; Ware T; McKew J; Fields FO; Bain LJ; Bens C
Expert Rev Neurother; 2015 Mar; 15(3):327-33. PubMed ID: 25708309
[TBL] [Abstract][Full Text] [Related]
19. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
Fillit H; Cummings J
Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691
[TBL] [Abstract][Full Text] [Related]
20. Study partners: essential collaborators in discovering treatments for Alzheimer's disease.
Largent EA; Karlawish J; Grill JD
Alzheimers Res Ther; 2018 Sep; 10(1):101. PubMed ID: 30261910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
